MedTrace Logo

Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371

NCT02540460 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-09-04

No results posted yet for this study

Summary

The purpose of this study is to investigate the population pharmacokinetics of LCB01-0371 after a multiple oral dose in healthy male subjects.

To investigate safety, tolerability of LCB01-0371 after a multiple oral dose in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

LCB01-0371 800mg

LCB01-0371 800mg

DRUG

LCB01-0371 800mg BID

LCB01-0371 800mg BID

DRUG

LCB01-0371 1200mg BID

LCB01-0371 1200mg BID

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Young Lag Cho, Ph.D. · Legochembioscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • South Korea

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02540460 on ClinicalTrials.gov